Alvotech (ALVOW)Luxembourg, Luxembourg | NasdaqGM
0.15 USD
|
Hot Take ↕ | July 11, 2026, 4:50 a.m. EDT
The immediate outlook is severely bearish due to catastrophic earnings deterioration, with quarterly earnings growth plummeting nearly 100% and annual earnings growth similarly collapsing. The business is burning significant cash, with operating cash flow and free cash flow both deeply negative, indicating a lack of self-sustaining operations. While the company holds a modest amount of cash relative to its massive debt load, the balance sheet is fragile, and the negative book value suggests the market values the assets at less than nothing. There is no dividend to provide any income cushion, and the price action shows no signs of recovery, trading near its 52-week low. The absence of any analyst recommendations and the complete lack of price history data further compound the uncertainty, making this a high-risk speculative vehicle rather than an investment. |
| Attribute | Value |
|---|---|
| Revenue per Share | 1.923 |
| Beta | 0.19 |
| Profit Margins | -14.36% |
| Website | https://www.alvotech.com |
| Attribute | Value |
|---|---|
| Address1 | 9, Rue de Bitbourg |
| Ask | 1.3 |
| Ask Size | 2 |
| Beta | 0.192 |
| Bid | 1.24 |
| Bid Size | 1 |
| Book Value | -0.904 |
| City | Luxembourg |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Luxembourg |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.15 |
| Current Ratio | 1.755 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.15 |
| Day Low | 0.15 |
| Earnings Growth | -0.99 |
| Earnings Quarterly Growth | -0.991 |
| Ebitda | 104,241,000 |
| Ebitda Margins | 0.18547001 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.15 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.15 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 0.15 - 0.15 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,783,690,200,000 |
| Float Shares | 123,166,274 |
| Free Cashflow | -92,554,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 1,279 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.61534 |
| Gross Profits | 345,844,992 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,022-06-16 |
| Language | en-US |
| Long Business Summary | Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg. |
| Long Name | Alvotech |
| Market | us_market |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_693209405 |
| Net Income To Common | -80,731,000 |
| Open | 1.52 |
| Operating Cashflow | -123,175,000 |
| Operating Margins | 0.091309994 |
| Previous Close | 0.15 |
| Price Hint | 4 |
| Price To Book | -0.16592921 |
| Profit Margins | -0.14364 |
| Quick Ratio | 0.67 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.15 |
| Regular Market Day Low | 0.15 |
| Regular Market Day Range | 0.15 - 0.15 |
| Regular Market Open | 1.52 |
| Regular Market Previous Close | 0.15 |
| Regular Market Price | 0.15 |
| Regular Market Time | 1,783,605,624 |
| Regular Market Volume | 0 |
| Return On Assets | 0.03839 |
| Revenue Growth | -0.202 |
| Revenue Per Share | 1.923 |
| Sand P52 Week Change | 0.20847368 |
| Sector | |
| Sector Key | |
| Short Name | Alvotech Warrant |
| Source Interval | 15 |
| Symbol | ALVOW |
| Total Cash | 63,832,000 |
| Total Cash Per Share | 0.204 |
| Total Debt | 1,457,281,024 |
| Total Revenue | 562,043,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 0 |
| Website | https://www.alvotech.com |
| Zip | 1,273 |